Susquehanna International Group
PRQR icon

Susquehanna International Group’s ProQR Therapeutics PRQR Stock Holding History

Susquehanna International Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,400
Closed -$48.8K – 13244
2024
Q4 		$48.8K Buy
18,400
+2,800
+18% +$8.89K ﹤0.01% 11688
2024
Q3 		$28.4K Buy
+15,600
New +$29.3K ﹤0.01% 11544
2023
Q2 		– Sell
-118,100
Closed -$252K – 12909
2023
Q1 		$252K Buy
118,100
+83,200
+238% +$254K ﹤0.01% 10105
2022
Q4 		$129K Buy
+34,900
New +$45.7K ﹤0.01% 10678
2022
Q2 		– Sell
-19,100
Closed -$17K – 13712
2022
Q1 		$17K Buy
19,100
+4,300
+29% +$14.4K ﹤0.01% 12668
2021
Q4 		$119K Sell
14,800
-42,700
-74% -$325K ﹤0.01% 12007
2021
Q3 		$481K Buy
+57,500
New +$376K ﹤0.01% 9492
2021
Q2 		– Sell
-97,000
Closed -$641K – 13108
2021
Q1 		$641K Buy
+97,000
New +$496K ﹤0.01% 8895

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Susquehanna International Group's PRQR Position: Q1 2026 in Review

Susquehanna International Group opened a new position in ProQR Therapeutics (PRQR) in Q1 2026: 12,206 shares worth $19.8K. The stake represents ﹤0.01% of the portfolio and ranks #12864 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in PRQR as recently as Q3 2025.

Susquehanna International Group first reported a position in PRQR in Q4 2017 and has held it in 19 quarters since. The position peaked at $1.07M in Q3 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Susquehanna International Group held 12,206 shares of ProQR Therapeutics worth $19.8K as of Q1 2026.
  • ProQR Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • ProQR Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12864 holding.
  • Susquehanna International Group first reported a position in ProQR Therapeutics in Q4 2017 and has held it in 19 quarters since.
  • Susquehanna International Group's ProQR Therapeutics position peaked at $1.07M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.